



# UNITED STATES PATENT AND TRADEMARK OFFICE

10D  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/489,079	01/21/2000	Patricia A. Billing-Medel	6451.US.P1	5338
23492	7590	09/15/2004	EXAMINER	
STEVEN F. WEINSTOCK ABBOTT LABORATORIES 100 ABBOTT PARK ROAD DEPT. 377/AP6A ABBOTT PARK, IL 60064-6008				ASHEN, JON BENJAMIN
ART UNIT		PAPER NUMBER		
		1635		
DATE MAILED: 09/15/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.	09/489,079	
Examiner	BILLING-MEDEL ET AL. Jon B. Ashen	
Art Unit	1635	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

1) Responsive to communication(s) filed on 24 June 2004.

2a) This action is **FINAL**.      2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

4) Claim(s) 52-61, 69 and 77-81 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 52-61, 69 and 77-81 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

9) The specification is/objection to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All    b) Some \* c) None of:  
1. Certified copies of the priority documents have been received.  
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

1) Notice of References Cited (PTO-892)  
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_

4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_

5) Notice of Informal Patent Application (PTO-152)

6) Other: \_\_\_\_\_

## **DETAILED ACTION**

### ***Status of the Application***

1. Claims 52-61, 69 and 77-81 are pending in this application. Applicant has canceled claims 62-68 and 70-76.

### ***Claim Rejections - 35 USC § 112***

2. Claims 57-58, 61, 77-79 and 81 remain rejected under 35 U.S.C § 112, 1<sup>st</sup> paragraph as failing to comply with the written description requirement for the reasons of record set forth in the prior Office action of 3/24/2004.

### ***Response to Arguments***

3. Applicant's arguments filed 6/24/2004 with respect to the rejection of record under 35 U.S.C §112 1<sup>st</sup> have been fully considered but they are not persuasive. Applicant traverses the instant rejection on the grounds that the specification adequately describes the polypeptides encompassed within the scope of the invention being claimed because Applicant has provided the complete structure of the claimed polypeptides as demonstrated by SEQ ID NOS: 24-28. (pg. 8, last paragraph, sentence continues to the top of page 9). However, as set forth in the prior Office action of 3/24/2004, the specification and claims do not place any limit on the number of amino acid substitutions, deletions, insertions and/or additions that may be made to the claimed

Art Unit: 1635

polypeptides, it is only required that a BS322 polypeptide contains at least 50% identity to the polypeptide sequences according to SEQ ID NOS: 24-28.

Applicant has therefore not provided the complete structure of a BS322 polypeptide contains at least 50% identity to the polypeptide sequences according to SEQ ID NOS: 24-28.

Applicant also contends that one of ordinary skill in the art would clearly recognize that Applicant had possession of the claimed invention because the level of skill in the area of molecular biology is considerably high such that after review of Applicant's specification, one of ordinary skill in the art would recognize that Applicants have provided an adequate written description of the variants, substitutions, deletions and/or additions encompassed by the claims. However, as was set forth in the prior Office action, the general knowledge and level of skill in the art do not supplement the omitted description because specific, not general, guidance is required. The genus of polypeptides as claimed, is highly variant as per Applicants disclosure on page 30 of the instant specification. The disclosure, however, fails to provide the relevant, identifying characteristics of the genus as claimed, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus.

Applicants also argue that insufficient factual evidence is presented by the Examiner to rebut the presumption of inadequate description and that the Examiner fails to present any factual evidence as to why a person of ordinary

Art Unit: 1635

skill in the art would not recognize in Applicants disclosure, a description of the invention as defined by the claims.

Applicant's attention is drawn to the MPEP §2163, which states, "The fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, applicant was in possession of the invention as now claimed. See, e.g., Vas-Cath, Inc., 935 F.2d at 1563-64, 19 USPQ2d at 1117." It is pointed out to Applicant that factual evidence was presented by the Examiner in regards to the lack of written description wherein it was set forth in the prior Office action that no common structural attributes were set forth which would provide the required common function shared among the members of the claimed genus of polypeptides such that one of skill in the art could clearly distinguish members of this genus.

4. Applicant's arguments, see page 6, 4<sup>th</sup> paragraph, filed 6/24/2004, with respect to the rejection of claims 77-78 under 35 U.S.C. §112 2<sup>nd</sup> paragraph have been fully considered and are persuasive. The rejection of record has been withdrawn.

#### ***Claim Rejections - 35 USC § 101***

5. The rejection of claims 52-61, 69 and 77-81 under 35 U.S.C § 101 and 112 is maintained for the grounds of rejection set forth in the prior Office action, mailed 3/24/2004.

***Response to Arguments***

6. Applicant's arguments filed 6/24/2004 have been fully considered but they are not persuasive.

Applicant argues that the basis of the Examiner's rejection stating that Jaeger et al. disclose splice variants of NY-BR-1 that are highly similar to each other is unclear (pg 11, 2<sup>nd</sup> paragraph). The following rationale is presented as clarification. As set forth in the prior Office action and as pointed out by Applicant in the instant communication, the NY-BR-1 splice variants of Jaeger et al. are highly similar, differing by only 111 bp. Applicant has argued previously that, based on nucleotide similarity, BS322 is a splice variant of NY-BR-1 (communication filed 11/06/2003, pg 3). However, it is noted herein that the nucleotide sequence of BS322 is disclosed as 2683 base pairs in length while the nucleotide sequence of NY-BR-1 is disclosed as 4463 base pairs in length. Given the large length differences between these two molecules as compared to the differences observed between NY-BR-1 and the known NY-BR-1 splice variants of Jaeger et al., sound scientific reasoning dictates that specific and particular evidence of the alternative splicing and maturation of a splice variant that is the considerably shorter BS322 nucleotide sequence (as compared to NY-BR-1) would be required to demonstrate that BS322 was indeed a splice variant of NY-BR-1.

Applicant also contends that they are not required to show that the claimed polypeptides are derived from both [splice] variants, if both variants are linked to breast disease but that Applicant is required only to show that the

claimed polypeptides are derived from one polynucleotide which is linked to breast disease (pg 11, 2<sup>nd</sup> paragraph). This argument is moot however, because applicant is required to show that the claimed polypeptides are useful in the method of the invention as claimed and applicant has not shown how BS322 is a polynucleotide that is linked to breast disease.

Applicants also contend that the specification clearly shows how SEQ ID NOS: 24-28 are derived from a polypeptide that is shown to be linked to breast disease (pg. 11, last sentence). However, it is respectfully pointed out that SEQ ID NOS: 24-25 are different polypeptides derived from alternative translations of a single polynucleotide (SEQ ID NO: 9), as disclosed on page 64 of the instant specification. In the instant case it is not clear how different polypeptides, translated from different but overlapping reading frames, can be derived from a single polypeptide. Additionally, no evidence is presented for a single polypeptide that is shown to be linked to breast disease in view of the Jaeger et al. reference. Therefore, Applicant has presented no evidence that SEQ ID NOS: 24-28 are derived from a single polypeptide that has been shown to be linked to breast disease.

Applicants also argue, with respect to the previous grounds of rejection that considers that Applicant has not provided objective evidence that the individual peptides according to SEQ ID NOS: 24-28 represent actual NY-BR-1 antigen epitopes, that the description of epitopes, a structural feature of the claimed polypeptides, is not easily describable by words (pg. 12, 2<sup>nd</sup> and 3<sup>rd</sup> paragraphs). Therefore, Applicant submits that the significance of the structure

of the polypeptides are described via their SEQ ID NO: as allowed in the Eli Lilly cases discussed in the USPTO Written description guidelines. Applicant's attention is drawn to MPEP § 2163 which states that the written description requirement may be satisfied through disclosure of function and minimal structure when there is a well-established correlation between structure and function. In contrast, without such a correlation, the capability to recognize or understand the structure from the mere recitation of function and minimal structure is highly unlikely. In this latter case, disclosure of function alone is little more than a wish for possession; it does not satisfy the written description requirement. See Eli Lilly, 119 F.3d at 1568, 43 USPQ2d at 1406. In the instant case, Applicant has not provided adequate written description of the epitopes of the invention because there is no disclosure of a structure-function relationship between the sequences of the polypeptides claimed that are SEQ ID NOS: 24-28 and the function of these sequences as epitopes. Rather, applicant has provided a mere recitation of function and minimal structure (as presented by primary sequence data depicted in contiguous strings of amino acid or nucleobase residues that are represented in U.S. Patent documents by SEQ ID NO:), which does not provide adequate written description. Therefore, applicants argument that the significance of the structure of the polypeptides of SEQ ID NO: 24-28 is described via their primary sequence does not overcome the grounds of the rejection of record because it does not provide objective evidence that the individual peptides according to SEQ ID NOS: 24-28 represent actual NY-BR-1 antigen epitopes.

Applicant further argues that their disclosure, in describing methods such as complex formation of immunogenic specific binding members using the claimed polypeptides and disclosing the exact amino acid sequences of polypeptides according to SEQ ID NOS: 24-28 provides objective evidence that demonstrates that the individual peptides according to SEQ ID NOS: 24-28 represent actual NY-BR-1 antigen epitopes (pg. 13, 2<sup>nd</sup> paragraph). Applicant points to *Noelle v. Lederman* (69 USPQ2d 1481 (CAFC 2004)) where the court held that a claim directed to an antibody which is capable of binding to a particular antigen has sufficient support in the written description that discloses “fully characterized” antigens. However, the finding of the Court in the above case considers that sufficient support in the written description relies on “fully characterized” antigens. In the instant case, applicant’s antigens are not fully characterized for the reasons set forth in the preceding paragraph. Therefore, because applicant does not have adequate written description of the particular BS322 antigens to which an antibody is capable of binding, sufficient support is not present for claims to said antibody.

Lastly, Applicant argues that their claims are not drawn to a method of directly curing diseases of the breast although the claimed methods of detection of antibodies ultimately can be useful in treating diseases of the breast (pg. 13, 3<sup>rd</sup> paragraph). This argument is moot because the rejection of record considers that one of skill in the art would not accept on its face that applicant has provided any sufficient objective evidence for the asserted utility of the claimed

polypeptides as breast specific antigens that are useful as diagnostics for breast disease.

7. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jon B. Ashen whose telephone number is 571-272-2913. The examiner can normally be reached on 7:30 am - 4:30 pm.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John LeGuyader can be reached on 571-272-0670. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1635

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public. For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.

Jba



SEAN McGARRY  
PRIMARY EXAMINER  
1635